POST Online Media Lite Edition



 

Agios Pharmaceuticals: David Schenkein CEO, Duncan Higgons COO

Staff writer |
Cambridge, Mass., USA - May 27, 2009, Cambridge, Mass., USA - Agios Pharmaceuticals announced the appointment of David Schenkein as CEO, effective August, and Duncan Higgons as COO, effective May.



Currently, Dr. Schenkein serves as Senior Vice President, Clinical Hematology/Oncology at Genentech with responsibility for leading the medical and scientific strategies for the Development BioOncology portfolio, as well as overseeing the BioOncology Clinical Science and Medical Science Liaison functions with a staff of more than 130 people.

He is currently an adjunct Professor of Medicine at the Stanford University Cancer Center. Before his tenure at Genentech, he served as Senior Vice President of Clinical Research at Millennium Pharmaceuticals. Prior to Millennium he was Director of the Cancer Center and Lymphoma Service at Tufts Medical Center.

Prior to joining Agios, Mr. Higgons served as Chief Operating Officer, President and interim Chief Executive Officer at Archemix where he was promoted to that position after serving as Archemix’s Executive Vice President, leading the company’s business operations.

Formerly, Mr. Higgons served as Chief Commercial Officer for TransForm Pharmaceuticals, a privately held biotechnology company that was acquired by Johnson & Johnson and as Senior Vice President, Business Development and Marketing for Alkermes, Inc.

LATEST 5 MOVES FROM Massachusetts 


What to read next

bluebird bio adds two to its board of directors
Adaptimmune strengthens board with new appointment
Agios Pharmaceuticals names chief commercial officer